Artemisia capillaris extract protects against bile duct ligation-induced liver fibrosis in rats

作者：Han, Jong-Min; Kim, Hyeong-Geug; Choi, Min-Kyung; Lee, Jong-Suk; Lee, Jin-Suk; Wang, Jing-Hua; Park, Hye-Jung; Son, Seung-Wan; Hwang, Seock-Yeon; Son, Chang-Gue^*

来源：Experimental and Toxicologic Pathology, 2013, 65(6): 837-844.

DOI：10.1016/j.etp.2012.12.002

• Artemisia capillaris Thunb
• Cholestasis
• Bile duct ligation
• Liver fibrosis

Artemisia capillaris has been widely used as a traditional herbal medicine in the treatment of liver diseases. However, no previous study has investigated whether A. capillaries alone is effective in treating pathological conditions associated with cholestatic liver injury. In the present study, we evaluated the anti-hepatofibrotic effects of A. capillaris (aqueous extract, WAC) in a bile duct ligation (BDL)-induced cholestatic fibrosis model. After BDL, rats were given WAC (25 or 50 mg/kg) or urosodeoxycholic acid (UDCA, 25 mg/kg) orally for 2 weeks (once per day). The serum cholestatic markers, malondialdehyde, and liver hydroxyproline levels were drastically increased in the BDL group, while administering WAC significantly reduced these alterations. Administering WAC also restored the BDL-induced depletion of glutathione content and glutathione peroxidase activity. Cholestatic liver injury and collagen deposition were markedly attenuated by WAC treatment, and these changes were paralleled by the significantly suppressed expression of fibrogenic factors, including hepatic alpha-smooth muscle actin (alpha-SMA), platelet-derived growth factor (PDGF), and transforming growth factor beta (TGF-beta). The beneficial effects of WAC administration are associated with antifibrotic properties via both upregulation of antioxidant activities and downregulation of ECM protein production in the rat BDL model.

• 出版日期2013-9